{
    "clinical_study": {
        "@rank": "149877", 
        "brief_summary": {
            "textblock": "The pharmacokinetic behavior of vincristine in pediatric patients has not been well\n      characterized.  The present study will obtain detailed information on vincristine\n      pharmacokinetics in patients being treated for standard risk ALL on CCG protocols 1952/1962.\n       A limited sampling strategy will be developed, and the interpatient and intrapatient\n      variability of vincristine pharmacokinetics in children will be studied.  A correlation\n      between vincristine neurotoxicity and vincristine pharmacokinetics will be sought."
        }, 
        "brief_title": "A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia", 
        "completion_date": "November 2003", 
        "condition": [
            "Acute Lymphocytic Leukemia", 
            "Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "The pharmacokinetic behavior of vincristine in pediatric patients has not been well\n      characterized.  The present study will obtain detailed information on vincristine\n      pharmacokinetics in patients being treated for standard risk ALL according to or on CCG\n      protocols 1952/1962/1991.  A limited sampling strategy will be developed, and the\n      interpatient and intrapatient variability of vincristine pharmacokinetics in children will\n      be studied.  A correlation between vincristine neurotoxicity and vincristine\n      pharmacokinetics will be sought."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n        All patients 1 year and less than 10 years of age.\n\n        Patient must be diagnosed with acute lymphoblastic leukemia.\n\n        All CCG patients must be enrolled on CCG 1952, 1962 or 1991 protocols, or be treated\n        according to a CCG standard risk ALL protocol.  NCI patients must be treated according to\n        CCG 1952 for the treatment  of standard risk ALL.  Enrollment onto the current trial (CCG\n        B9802) should if possible take place concurrently with enrollment onto 1952/1962/1991 or\n        start of treatment according to a CCG standard risk ALL protocol.\n\n        All patients or their legal guardians must sign a document of informed consent indicating\n        their awareness of the investigational nature and the risks of this study.\n\n        EXCLUSION CRITERIA:\n\n        Previous underlying peripheral neuropathy.\n\n        Previous underlying central nervous system dysfunction.\n\n        Children with CNS toxicity attributable to other chemotherapeutic agents will not be\n        followed with the Purdue pegboard test."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "90", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001689", 
            "org_study_id": "980053", 
            "secondary_id": "98-C-0053"
        }, 
        "intervention": {
            "intervention_name": "Vincristine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Vincristine"
        }, 
        "keyword": [
            "Neurotoxicity", 
            "A.L.L.", 
            "Limited Sampling", 
            "Dose Individualization", 
            "Vinca Alkaloids"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "7931891", 
                "citation": "Crom WR, de Graaf SS, Synold T, Uges DR, Bloemhof H, Rivera G, Christensen ML, Mahmoud H, Evans WE. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994 Oct;125(4):642-9."
            }, 
            {
                "PMID": "7700168", 
                "citation": "de Graaf SS, Bloemhof H, Vendrig DE, Uges DR. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1995 Apr;24(4):235-40."
            }, 
            {
                "PMID": "2262483", 
                "citation": "Adamson PC, Poplack DG, Balis FM. Pharmacology and drug resistance in childhood lymphoblastic leukemia. Hematol Oncol Clin North Am. 1990 Oct;4(5):871-94. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001689"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1998", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2003"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}